Patents
Sitemap › C07 - Organic chemistry › C07K - Peptides
More topics under "C07K - Peptides" (616,656)
C07K 1 - General processes for the preparation of peptides (51,718)
C07K 11 - Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof (895)
C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526)
C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320)
C07K 17 - Carrier-bound or immobilised peptides; Preparation thereof (10,673)
C07K 19 - Hybrid peptides (29,428)
C07K 2 - Peptides of undefined number of amino acids; Derivatives thereof (4,723)
C07K 4 - Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof (2,102)
C07K 5 - Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof (30,692)
C07K 7 - Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof (42,273)
C07K 9 - Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof (3,306)
Patents for C07K - Peptides (3,738)
12/2005
12/29/2005US20050287648 Protein Transducing Domain/Deaminase Chimeric Proteins, Related Compounds, and Uses Thereof
12/29/2005CA2570130A1 Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof
12/29/2005CA2568601A1 Peptide-based compounds
12/28/2005EP1608409A2 Peptides selectively lethal to malignant and transformed mammalian cells
12/28/2005EP1608393A2 Ebola peptides and immunogenic compositions containing same
12/28/2005EP1608373A2 Tie-2 modulators and methods of use
12/28/2005EP0920448B1 Truncated glial cell line-derived neurotrophic factor
12/28/2005CN1714101A Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells.
12/27/2005US6979726 Immunoconjugates
12/22/2005WO2005121171A1 Proteins stabilizing hydrophobic molecules
12/22/2005WO2005037855A3 T cell epitopes useful in a yersinia pestis vaccine and as diagnostic tools and methods for identifying same
12/22/2005WO2005019241A3 Cationic antimicrobial peptides and compositions thereof
12/22/2005WO2004111074A3 In vivo production of a clostridial neurotoxin light chain peptide
12/22/2005WO2004048399A3 Skin or hair binding peptides
12/21/2005EP1606065A2 Methods and materials for nanocrystalline surface coatings and attachment of peptide amphiphile nanofibers thereon
12/21/2005CN1232644C Optimization method for activation of endogenetic gene of cell
12/15/2005WO2005118613A2 Antibacterial amide macrocycles
12/15/2005WO2004041842A3 Epitopes of hepatitis c virus
12/15/2005WO2004029072A3 PrPsc -INTERACTING MOLECULES AND USES THEREOF
12/15/2005DE102004025731A1 Antibakterielle Amid-Makrozyklen III Antibacterial amide macrocycles III
12/14/2005EP1605052A2 A method for producing influenza hemagglutinin multivalent vaccines
12/08/2005WO2005116052A2 ANTAGONISM OF TGF-β SUPERFAMILY RECEPTOR SIGNALING
12/08/2005WO2005115097A2 Cyclic peptide antibiotics
12/08/2005US20050272778 Inhibitors of proteins that bind phosphorylated molecules
12/08/2005US20050272662 Self-assembled peptide-amphiphiles & self-assembled peptide nanofiber networks presenting multiple signals
12/08/2005US20050272648 Ghrelin analogs
12/08/2005US20050271655 Nogo receptor antagonists
12/08/2005CA2563374A1 Antagonism of tgf-.beta.superfamily receptor signaling
12/07/2005EP1601684A2 Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease
12/07/2005EP1601683A2 Novel non-invasive marker for liver disease
12/07/2005CN1230539C Bacterial auto-inducer inactivation protein, its coded nucleic acid molecule and uses
12/07/2005CN1230536C Tie-2 ligands, methods of making and uses thereof
12/07/2005CN1230441C Integrin binding peptide derivatives
12/01/2005WO2005058938A3 Helical synthetic peptides that stimulate cellular cholesterol efflux
12/01/2005WO2005051977A3 Conditional allele system
12/01/2005WO2005026191A3 Size-controlled macromolecule
11/2005
11/30/2005CN1703425A Crystallization of IGF-1
11/30/2005CN1229390C Peptides that lower blood glucose levels
11/30/2005CN1229388C N-terminal modified protein compositions and methods therefor
11/24/2005WO2005111214A1 Ethanol productivities of saccharomyces cerevisiae strains in fermentation of dilute-acid hydrolyzates depend on their furan reduction capacities
11/24/2005WO2005051978A3 Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof
11/24/2005WO2005047306A3 A prion-like form of cpeb and related compositions and methods
11/24/2005US20050260707 Corynebacterium glutamicum genes encoding metabolic pathway proteins
11/24/2005CA2567109A1 Ethanol productivities of saccharomyces cerevisiae strains in fermentation of dilute-acid hydrolyzates depend on their furan reduction capacities
11/23/2005EP1597278A2 Polyethylene glycol modified interferon compositions and methods of use thereof
11/23/2005EP1597274A2 Hsp60 from arthrobacter
11/23/2005EP0835305B1 Cytokine that induces apoptosis
11/22/2005US6967091 Lowering circulating free fatty acid levels in an individual by administering to polypeptide and carrier
11/17/2005WO2005108426A1 Peptide stabilization
11/17/2005WO2005047309A3 Prophylactic and therapeutic monoclonal antibodies
11/17/2005WO2005021577A3 Novel plant glycine and histidinie-rich metal-binding protein family and uses thereof
11/17/2005WO2004073736A8 Attenuated strains of vibrio cholerae and lyophilised vaccines containing same
11/17/2005US20050256161 Melanin concentrating hormone receptor antagonists
11/17/2005US20050256056 Peptide inhibitors of HIV
11/17/2005US20050256049 Chimeric toxins for targeted therapy
11/17/2005US20050255531 Signal transduction
11/16/2005EP1594889A2 Nell peptide expression systems and bone formation activity of nell peptide
11/16/2005EP1594845A2 Benzene acetamide compounds useful as serine protease inhibitors
11/16/2005EP1594529A2 Analogues of glp-1
11/16/2005EP1594518A2 Novel peptide inhibitor of hiv fusion that disrupts the internal trimeric coiled-coil of gp41
11/16/2005EP1594505A2 Phenylglycine derivatives useful as serine protease inhibitors
11/16/2005EP1594436A2 Polymer conjugates of mutated neublastin
11/10/2005WO2005054272A3 Human immunodeficiency virus entry inhibitor assay
11/10/2005US20050250680 Treating leukemia by administering a cross-linked polypeptide antiapoptosis agent having at least two modified amino acids ("hydrocarbon stapling"); crosslinking increases cell permeability
11/09/2005EP1592707A2 Hmgb1 modulator binding domain
11/09/2005EP0769024B1 High-affinity melatonin receptors and uses thereof
11/09/2005CN1694723A Vaccine
11/08/2005US6962970 Glycopeptide derivatives and pharmaceutical compositions containing the same
11/02/2005EP1590663A2 Immunocompromised rodents as dual color tumor models
11/02/2005EP1590365A2 Mycobacterial diagnostics
11/02/2005CN1691963A Treatment of tnfalpha related disorders
11/02/2005CN1690077A Compositions for the therapy and diagnosis of prostate cancer and its uses
11/02/2005CN1225473C Method of preparing cyclic vasoactive peptides
10/2005
10/27/2005WO2005044838A8 Cd4+ epitopes of bone morphogenetic proteins
10/27/2005WO2005037854A3 Immunogenic peptides
10/27/2005WO2005000870A3 Isolated ny-eso-1 peptides which bind to hla class ii molecules and uses thereof
10/27/2005WO2004081030A8 Peptides selectively lethal to malignant and transformed mammalian cells
10/27/2005US20050239690 Intermediate for preparing glycopeptide derivatives
10/26/2005EP1587820A2 Isoform specific interactions of apolipoprotein e to an intermediate conformation of alzheimer a beta peptide
10/26/2005EP1587541A2 Compositions and methods of tolerizing a primate to an antigen
10/26/2005CN1688631A Water-soluble polymer alkanals
10/20/2005US20050233969 Analogues of GLP-1
10/19/2005EP1585764A2 Rantes-derived peptides with anti-hiv activity
10/19/2005EP1585757A2 Peptide deformylase inhibitors
10/19/2005EP0846173B1 Use of an anti-interleukin-9 antibody for the preparation of a medicament for the treatment of asthma
10/19/2005CN1685064A Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome
10/13/2005WO2005056577A3 Peptide inhibitors of hiv
10/13/2005WO2005003150A3 Compositions and methods for use of a protease inhibitor and adenosine for preventing organ ischemia and reperfusion injury
10/13/2005DE60104282T2 Lösliche mutante ctla4 moleküle und deren verwendung Soluble CTLA4 mutant molecules and their use
10/12/2005CN1681838A Nogo受体拮抗剂 Nogo receptor antagonist
10/06/2005WO2005042559A3 Capture and release based isotope tagged peptides and methods for using the same
10/06/2005WO2005028496A3 Vaccine for treatment and prevention of herpes simplex virus infection
10/06/2005US20050222009 Dual phase - PNA conjugates for the delivery of PNA through the blood brain barrier
10/06/2005US20050221400 Monoclonal antibody comprising an antigen binding site that binds specifically to PSCA protein wherein monoclonal antibody comprises the amino acid sequence of the variable heavy chain region and the variable light chain region of antibody secreted by hybridoma assigned A.T.C.C. Accession No.: PTA-6697
10/06/2005US20050220797 Prophylactic and therapeutic monoclonal antibodies
10/05/2005EP1581309A2 Kinase modulators
09/2005
09/29/2005WO2005051976A3 Protein and peptide ligation processes and one-step purification processes
09/29/2005WO2005012329A3 Kinase and phosphatase assays
09/29/2005WO2005007674A3 Anti-human vitronectin antibody and methods for making the same
09/29/2005US20050215477 Treating agonist disorderssuch asd diabetes, obesity, heart dysfunctions, AIDS-related wasting, and kidney, neurological, whole body growth disorders by administering a crystal of an insulin-like growth factor-1 that diffracts x-ray radiation to produce a three-dimensional diffraction pattern
1 ... 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 ... 38